Enterprise Value
-9.555M
Cash
32.37M
Avg Qtr Burn
-3.284M
Short % of Float
0.52%
Insider Ownership
11.27%
Institutional Own.
40.08%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ATRN-119 Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
APR-1051 Details Solid tumor/s, Cancer | Phase 1 Update | |
Eprenetapopt (APR-246) + azacitidine Details Acute myeloid leukemia, Cancer, Myelodysplastic syndrome | Failed Discontinued | |
Eprenetapopt (APR-246) + Azacitidine Details Blood disorder, Myelodysplastic syndrome | Failed Discontinued | |
APR-548 + azacitidine Details Mutant Myelodysplastic Syndromes | Failed Discontinued |